A Study on the Anticarcinogenic Effects of Calcium Fructoborate
| dc.contributor.author | Tepedelen, Burcu Erbaykent | |
| dc.contributor.author | Korkmaz, Mehmet | |
| dc.contributor.author | Tatlisumak, Ertugrul | |
| dc.contributor.author | Uluer, Elgin Tukoz | |
| dc.contributor.author | Olmez, Ercument | |
| dc.contributor.author | Degerli, Ismail | |
| dc.contributor.author | Soya, Elif | |
| dc.date.accessioned | 2023-06-16T12:48:17Z | |
| dc.date.available | 2023-06-16T12:48:17Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | Evidences about the preventive and therapeutic effects of boron compounds on cancer have been increasing in the last years. Although calcium fructoborate (CaFB) is used as a nutritional supplement, data about its preventive and therapeutic effects on neoplastic transformations are limited. In the present study, the various concentrations of CaFB were applied to the MDA-MB-231 metastatic breast cancer cell line. First, we examined the cytotoxic effect and IC50 value of CaFB by MTT assay. For the evaluation of the DNA damage, apoptosis and metastatic potential, expression levels of ATM, pATM, PARP, p53, p-p53, caspase-3, caspase-9, and VEGF were investigated by using immunoblotting and immunohistochemical methods. Cell viability was significantly reduced at 50 mu M CaFB treatment. pATM, p-p53, and caspase-9 levels increased significantly in all groups; furthermore, there was approximately 12.5-, 2.4-, and 10.7-fold increase, respectively, for 100 mu M CaFB treatment. ATM and p53 levels did not change with CaFB treatment, but PARP levels significantly 2.5-fold decreased. While VEGF immunoreactivity decreased in all groups, significant increase in caspase-3 immunoreactivity was observed only in the group treated with 50 mu M CaFB ( p < 0,001). Our results imply that CaFB may have therapeutic potential as well as preventive benefits in cancer. | en_US |
| dc.description.sponsorship | Turkish Scientific and Technological Research Council [TUBITAK 113S700] | en_US |
| dc.description.sponsorship | This research was supported with grants (TUBITAK 113S700) from the Turkish Scientific and Technological Research Council. | en_US |
| dc.identifier.doi | 10.1007/s12011-016-0918-6 | |
| dc.identifier.issn | 0163-4984 | |
| dc.identifier.issn | 1559-0720 | |
| dc.identifier.scopus | 2-s2.0-85007420804 | |
| dc.identifier.uri | https://doi.org/10.1007/s12011-016-0918-6 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/994 | |
| dc.language.iso | en | en_US |
| dc.publisher | Springernature | en_US |
| dc.relation.ispartof | Bıologıcal Trace Element Research | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | MDA-MB-231 | en_US |
| dc.subject | Boron | en_US |
| dc.subject | Calcium fructoborate | en_US |
| dc.subject | DNA damage | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | VEGF | en_US |
| dc.subject | Inhibits Human Prostate | en_US |
| dc.subject | Breast-Cancer | en_US |
| dc.subject | Dietary Boron | en_US |
| dc.subject | Boric-Acid | en_US |
| dc.subject | Phenylboronic Acid | en_US |
| dc.subject | Growth | en_US |
| dc.subject | Supplementation | en_US |
| dc.subject | Mechanisms | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | Migration | en_US |
| dc.title | A Study on the Anticarcinogenic Effects of Calcium Fructoborate | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Soya, Elif/0000-0002-7956-1315 | |
| gdc.author.id | Inan, Sevinc/0000-0003-1971-9720 | |
| gdc.author.scopusid | 47860936500 | |
| gdc.author.scopusid | 36677416200 | |
| gdc.author.scopusid | 6506838303 | |
| gdc.author.scopusid | 54584495800 | |
| gdc.author.scopusid | 6603585456 | |
| gdc.author.scopusid | 57192690813 | |
| gdc.author.scopusid | 57189218920 | |
| gdc.author.wosid | Korkmaz, Mehmet/N-8168-2015 | |
| gdc.author.wosid | Tepedelen, Burcu Erbaykent/AAH-6436-2021 | |
| gdc.author.wosid | Soya, Elif/AGE-9174-2022 | |
| gdc.author.wosid | uluer, elgin/AAN-2767-2021 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | metadata only access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [Tepedelen, Burcu Erbaykent; Korkmaz, Mehmet; Degerli, Ismail; Soya, Elif] Celal Bayar Univ, Dept Med Biol, Fac Med, TR-45030 Manisa, Turkey; [Tatlisumak, Ertugrul] Celal Bayar Univ, Dept Anat, Fac Med, TR-45030 Manisa, Turkey; [Uluer, Elgin Tukoz] Celal Bayar Univ, Dept Histol & Embryol, Fac Med, TR-45030 Manisa, Turkey; [Olmez, Ercument] Celal Bayar Univ, Dept Med Pharmacol, Fac Med, TR-45030 Manisa, Turkey; [Inan, Sevinc] Izmir Univ Econ, Dept Histol & Embryol, Fac Med, TR-35330 Izmir, Turkey | en_US |
| gdc.description.endpage | 217 | en_US |
| gdc.description.issue | 2 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.startpage | 210 | en_US |
| gdc.description.volume | 178 | en_US |
| gdc.description.wosquality | Q2 | |
| gdc.identifier.openalex | W2566327656 | |
| gdc.identifier.pmid | 28028787 | |
| gdc.identifier.wos | WOS:000405475800006 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.downloads | 4 | |
| gdc.oaire.impulse | 1.0 | |
| gdc.oaire.influence | 2.89945E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Cell Line, Tumor | |
| gdc.oaire.keywords | Borates | |
| gdc.oaire.keywords | Anticarcinogenic Agents | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Breast Neoplasms | |
| gdc.oaire.keywords | Female | |
| gdc.oaire.keywords | Fructose | |
| gdc.oaire.keywords | Drug Screening Assays, Antitumor | |
| gdc.oaire.keywords | Neoplasm Proteins | |
| gdc.oaire.popularity | 7.0483406E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 0303 health sciences | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.views | 2 | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 0.339 | |
| gdc.openalex.normalizedpercentile | 0.69 | |
| gdc.opencitations.count | 12 | |
| gdc.plumx.mendeley | 56 | |
| gdc.plumx.pubmedcites | 1 | |
| gdc.plumx.scopuscites | 11 | |
| gdc.scopus.citedcount | 11 | |
| gdc.wos.citedcount | 10 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 |
Files
Original bundle
1 - 1 of 1
